论文部分内容阅读
目的探讨氯沙坦钾联合吲达帕胺治疗原发性高血压病的临床疗效。方法选择2013年4月—2015年4月收治的90例原发性高血压病患者,随机分为观察组和对照组各45例,观察组经氯沙坦钾联合吲达帕胺治疗,对照组经苯那普利联合吲达帕胺治疗,比较两组临床疗效。结果两组患者治疗后收缩压与舒张压均显著低于治疗前,具有统计学意义(P<0.05);但两组患者血压变化比较无统计学意义(P>0.05)。治疗后观察组甘油三酯、K~+均显著低于对照组,差异具有统计学意义,P<0.05。结论原发性高血压病患者经氯沙坦钾联合吲达帕胺治疗,安全性较高,疗效确切,值得临床推广应用。
Objective To investigate the clinical efficacy of losartan plus indapamide in the treatment of essential hypertension. Methods From April 2013 to April 2015, 90 patients with essential hypertension were randomly divided into observation group and control group, 45 cases in each group. The observation group was treated with losartan potassium combined with indapamide, and the control group Group benazepril combined with indapamide treatment, the clinical efficacy of the two groups were compared. Results After treatment, the systolic and diastolic blood pressures of both groups were significantly lower than those before treatment (P <0.05). However, there was no significant difference in blood pressure between the two groups (P> 0.05). After treatment, triglyceride and K ~ + in the observation group were significantly lower than those in the control group, with statistical significance (P <0.05). Conclusions The treatment of losartan and indapamide in patients with essential hypertension is more safe and effective and worthy of clinical application.